1 Age-patterns of severity of clade I mpox in historically endemic countries

- 2 Lilith K Whittles^{1*}, Placide Mbala-Kingebeni^{2,3}, Neil M Ferguson¹
- 3 1. MRC Centre for Global Infectious Disease Analysis, and Jameel Institute, School of
- 4 Public Health, Imperial College London, 90 Wood Lane, London, W12 0BZ, UK
- 5 2. Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo
- 6 3. Service de Microbiologie, Département de Biologie médicale, Cliniques Universitaires de
- 7 Kinshasa, Université de Kinshasa
- 8 *Corresponding author: Lilith Whittles, Imperial College London, 90 Wood Lane, London,
- 9 W12 0BZ, UK. I.whittles@imperial.ac.uk

10 **ABSTRACT**

- 11 **Background** The last two years have seen mpox emerge as a notable pandemic threat. The
- 12 global 2022-23 outbreak of clade II mpox caused over 93,000 cases worldwide, while the
- 13 2023-24 epidemic of the more severe clade I virus in the Democratic Republic of Congo
- 14 (DRC) has caused over 14,000 cases and over 650 deaths thus far. Of particular concern is
- that both case incidence and mortality in the DRC outbreak are concentrated in children.
- However, quantification of age variation in severity for clade I infections has been lacking to
- 17 date.
- 18 **Methods** Using Bayesian binomial regression models, we analysed data from systematically
- 19 reviewed clade I outbreaks to estimate case fatality ratios (CFR) by age, smallpox
- 20 vaccination status and over time. We compared model predictive performance using leave-
- 21 one-out cross-validation and compared our findings to the ongoing DRC outbreak.
- Findings The CFR had a near-reciprocal relationship with age, declining from 9.7% (95%)
- 23 credible interval: 6.9%-13.0%) among 5-year-olds to 1.2% (95%Crl: 0.3%-3.7%) by age 30.
- 24 Accounting for vaccination status in addition to age did not improve model fit, but posterior
- 25 parameter estimates suggest substantial vaccine-protection against death. Reanalysis
- incorporating cases from the ongoing DRC outbreak suggested less steep declines in
- 27 severity with age and a protective effect of vaccination against death of 64% (95%Crl: -
- 28 3.4%-95.6%) and reduction in severity over time.
- 29 Interpretation We provide estimates of the mpox clade I CFR in historically endemic
- settings by vaccine status, and find the highest risk of death in the youngest children.
- 31 Funding Wellcome, NIHR, MRC, Community Jameel

INTRODUCTION

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

Mpox is a viral zoonosis endemic to sylvatic rodent populations in West and Central Africa that has caused spill-over outbreaks among humans since its discovery in 1970 (1). Vaccination against smallpox, another orthopoxvirus, provides cross-protection against mpox infection (2). Smallpox vaccination campaigns ceased after its global eradication in 1980 and while vaccine-conferred protection is long-lasting, demographic turnover has reduced population-level vaccine-coverage worldwide, with marked regional variation (3). Susceptibility to orthopoxviruses is therefore concentrated in individuals born after 1980, who have never been infected with smallpox and are unlikely to have been vaccinated against it. With the waning of population immunity, mpox outbreaks have been increasingly frequent (1). In 2022 this culminated in a global outbreak comprising over 93,000 cases across 117 countries, during which sexual transmission was noted for the first time and was the key driver, with cases heavily concentrated among men who have sex with men (MSM) (4).The mpox virus (MPXV) has been separated into distinct strains based on genetic differences: clade I (formerly known as the Congo Basin strain) and clade II (formerly the West African strain, a sub-clade of which, Ilb, was responsible for the 2022 outbreak) (5). Severity of human MPXV infection differs by strain, the case fatality ratio (CFR) for clade I has been estimated at 10.6% (95%CI 8.4%-13.3%) compared with 4.6% (95%CI 2.1%-8.6%) for clade II, based on cases in endemic regions (1), while the CFR in the 2022-23 global clade IIb outbreak was much lower at <0.1% (6). Biological evidence supports strainspecific differences in virulence; in mice, clade I was estimated to be 1000x more severe than clade II based on fatal outcomes, with no deaths observed in sub-clade IIb (5). In 2023 there were 14,626 suspected clade I mpox cases in the Democratic Republic of Congo (DRC), more than double the 6,216 cases recorded in 2020 (7,8). Sexual transmission of clade I mpox has been observed for the first time, with outbreaks among MSM networks and in commercial sex workers (7,8). However, unlike the clade IIb outbreak where over 95% of infections recording demographic data were among adult men (4), cases in the ongoing DRC epidemic have been concentrated in children, with 69% (3125/4538) of cases in the first 12 weeks of 2024 reported in under 15 year-olds, reflecting age-patterns observed in previous outbreaks in historically-affected countries (8). Furthermore, early evidence from DRC suggests that children under 15 years have accounted for 86% (254/296) of reported deaths in 2024, suggesting potential increased severity at young ages (8).

- 66 Age-specific variation in severity has important implications for understanding disease
- burden and how to best target interventions to reduce overall morbidity and mortality.
- However, there are currently no age-specific estimates of severity for mpox clade I.
- Furthermore, the extent to which age differences in severity can be explained by the
- 70 concentration of vaccine-coverage at older ages is unclear.
- Here, using data from systematically reviewed past outbreaks (1), we fitted mathematical
- 72 models to quantify the relationship between the case fatality ratio (CFR) of mpox clade I and
- age at infection, the impact of vaccination status (either confirmed, or inferred based on birth
- date) on CFR, and looked for evidence of temporal changes in severity. We repeated the
- analysis incorporating information from the ongoing outbreak in DRC to assess the impact
- on our estimates.

METHODS

Data

77

78

95

- 79 We extracted data from a 2022 systematic review (1) on 550 case outcomes and year of
- 80 symptom onset from studies reporting clade I outbreaks. Thirteen studies contained data on
- 81 125 individual cases including patient age and outcome (9–21). The individually reported
- 82 cases ranged in age from eight months to 41 years. A further three studies reported 425
- 83 case outcomes grouped by age-band (22–24). The youngest age band in the grouped data
- 84 was 0–3 years and the eldest was 40–69 years. Vaccination status of cases was recorded
- as 'confirmed' or 'unvaccinated' based on reported visual examination of vaccination scars.
- 86 For the remaining cases we assigned vaccination status as 'probable' or 'doubtful' based on
- 87 whether the patient was born before or after 1980, when routine smallpox vaccination
- ceased (3). We assessed the sensitivity of our findings to this assumption by repeating the
- 89 analysis excluding all cases assigned as 'probable'. We conducted supplementary analyses,
- assessing the impact of incorporating information from the ongoing outbreak in DRC,
- 91 extracting 4538 age-grouped case outcomes (<1y, 1-5y, 5-14y, 15y+) reported in the DRC
- 92 sitrep for the first 12 weeks of 2024 (11). We assigned 'doubtful' vaccination status to all
- 93 cases from the ongoing DRC outbreak, Including the 1413 aged over 15, implicitly assuming
- 94 that all cases were aged under 44 years (*i.e.* were born after 1980).

Statistical analysis

- 96 In an exploratory analysis, we grouped the case data into five-year bands according to both
- age (a) and year of infection (y), as well as by vaccination status (v) We compared patterns
- of cases (C_i) and deaths (D_i) in each group $j = \{a, y, v\}$, and calculated crude estimates of

the case fatality ratio by dividing the number of deaths by the number of cases $CFR_j = D_j/C_j$. We constructed exact 95% confidence intervals for the CFR using the by calculating the Clopper-Pearson interval.

We assessed the association between the CFR under each model, $p_M(\underline{x})$, and combinations of case covariates, including age (x_a) , year of onset (x_y) , and vaccination status x_v (where $x_v=1$ denotes probable or confirmed smallpox vaccination and $x_v=0$ denotes doubtful or no vaccination). When data was reported in age groups, we approximated the age of each case using the median age for each group, where reported, and otherwise calculated the midpoint of each age band. For the DRC data we assumed the average age of cases (and deaths) over the age of 15 was 34y, in line with national demography, and assessed the impact of our assumption in sensitivity analysis using a lower estimate of 21y.

We modelled the data using binomial regression and performed analyses both excluding and including the DRC sitrep data. We considered ten models (M1-M10) in total, allowing the CFR to depend on each of the three model covariates (age, vaccination status, year of onset) alone and in combination, and considering two different functional forms (logistic and Hill) for the dependency on age. For all models considered, the CFR can be represented in a generalised form:

116
$$p_M(\underline{x}) = \frac{f_M(\underline{x})}{1 + \left(\frac{g_M(x_a)}{g_M(a_{50})}\right)^b}$$

- Here b=0 in the models where the CFR does not depend on age, $g_{\{A=1\}}(x_a)=e^{x_a}$ in the
- logistic models, and $g_{\{A=2\}}(x_a)=x_a$ in the Hill function models. In models depending on age
- only, the numerator function $f_{\{V=0,Y=0\}}(x)=\theta$, where θ is a parameter specifying the value of
- $p_M(\underline{x})$ at age zero in unvaccinated individuals. For models including vaccination status,
- $f_{\{V=1,Y=0\}}(x) = \theta(1-\phi x_v)$, where ϕ denotes the relative difference in CFR for vaccinated
- versus unvaccinated individuals. In models including year, $f_{\{V=0,Y=1\}}(x) = \theta_{y=1970} + \theta_{y=1970}$
- $\frac{\theta_{y=2024}-\theta_{y=1970}}{2024-1970}x_y$, such that severity is assumed to vary linearly by year of onset between the
- 124 two fitted endpoints. Last, in models including both year and vaccination status
- $f_{\{V=1,Y=1\}}(x) = f_{\{V=1,Y=0\}} (f_{\{V=0,Y=1\}}(x)).$

- The model parameters can be intuitively interpreted, such that θ is the CFR at age zero for
- 127 unvaccinated individuals, with year of onset $\theta_{y \in \{1970,2024\}}$ where applicable; ϕ is the vaccine
- effectiveness against death given symptomatic infection; a_{50} is the age by which the CFR

130

131132

133

134

135

136

137

138

139140

141

142

143

144

145

146

147

148

149

150

151

152

153154

155

156157

158

159

has declined to half of its initial value of θ_{ν} ; and b controls the slope of the decline in CFR with age, where b = 1 describes a reciprocal relationship. We fitted the models in a Bayesian framework using the R package brms v2.20.4 which serves as a frontend for the probabilistic programming language Stan (25,26). We used weakly informative uniform priors such that $\{\theta_{\nu}\} \sim U(0,1)$, $a_{50} \sim U(0,70)$, and $b \sim U(0,3)$. For the estimate of vaccine protection against death we adopted a deliberately conservative prior, $\phi \sim U(-1,1)$, allowing parameter values below zero to enable the model to detect whether the protective effect was statistically significant. We obtained posterior parameter estimates for each model using an adaptive Hamiltonian Monte Carlo no U-turn sampler comprising four MCMC chains of 5,000 iterations each. We assessed convergence of the chains by ensuring the Gelman-Rubin criterion was ≈1 and the effective sample size (ESS) >1,000 for each parameter. We compared the predictive performance of the ten fitted models via leave-one-out crossvalidation, via the R package loo v2.6.0 (27) and applied a moment matching correction to the importance sampling for observations that were indicated as problematic, based on Pareto k diagnostic >0.7 (28). The data and code needed to reproduce the analysis are freely available at: https://github.com/mrc-ide/mpox clade i severity **RESULTS** Age and temporal trends in case data Across the period 1970-2020, most data arose from the reports of outbreaks in DRC in the early 1980s and late 1990s (Figure 1A) (22,23). Cases over the whole period were concentrated in young age groups, with 38.5% (n=212/550) in children under 5 years old (Figure 1B). Most cases were unlikely to have been vaccinated against smallpox, with 55.5% (n=305) confirmed unvaccinated and 27.6% (n=152) unlikely to have been vaccinated due to being born after 1980. Only 9.3% (n=51) had confirmed smallpox vaccine scars. We assigned the remaining 7.6% (n=42) 'probable' vaccination status based on birth date prior to 1980. When cases were disaggregated into five-year age and time bands, there was a clear trend of cases occurring more frequently in adults in recent years, likely associated with the reductions in the proportion of adults protected by prior smallpox vaccination over time (Figure 1C).




Figure 1 Number of cases recorded between 1970 and 2020 in studies identified by the Bunge et al. systematic review (1). A) in each five-year period over all ages, B) in each five-year age group over the whole period and C) split by both period and age. Stacked bars are coloured by vaccination status, where confirmed, and otherwise considered as 'probable' or 'doubtful' depending on whether an individual was born before or after 1980 (when routine smallpox vaccination ceased), respectively.

Patterns of case severity by age and vaccination status

The overall crude CFR estimate from the pre-2021 case data was 9.5% (n=52/550; 95%CI 7.1%-12.2%). We performed preliminary analysis of age-trends in severity by stratifying the case data into broad age groups (children aged under five years, 5-14 years and "adults" aged 15 and over) which revealed more severe outcomes at younger ages. We estimated a crude CFR of 17.5% (n=37/212; 95%CI 12.6%-23.2%) in under 5 year-olds compared to 7.4% (n=13/175; 95%CI 4.0%-12.4%) in children aged 5-14 and 2.4% (n=2/85; 95%CI 0.3%-

8.2%) in those aged 15 and over (Table 1)**Error! Reference source not found.**. A similar age-pattern of severity was also apparent in the 2024 DRC sitrep, although the decline in severity with age was less steep. The crude CFR in children under 5 was lower than the systematic review estimate with non-overlapping confidence intervals, at 10.5% (n=192/1832; 95%CI 9.1%-12.0%), declining to 4.8% (n=62/1293; 95%CI 3.7%-6.1%) in children aged 5-14 and 3.0% (n=42/1213; 95%CI 2.2%-4.0%) in those aged 15 and over.

Table 1 Analysis of crude CFR by age-group based on studies of clade I outbreaks included in Bunge et al. (1) only, and additionally incorporating 2024 DRC sitrep (8).

		Age band:	<5	<5y		5-14y		≥15y	
Country*	Author, year	Study period	Cases	Deaths	Cases	Deaths	Cases	Deaths	
DRC	Breman, 1980 (10)	1970-1979	23	6	11	2	4	0	
DRC	Jezek, 1986 (13)	May - Jul 1983	2	1	3	0	0	0	
DRC	Jezek, 1988 (22)	1981-1986	140	24	117	8	20	0	
CAR	Khodakevich, 1985 (17)	Jan 1984	0	0	0	0	1	0	
CAR	Herve, 1989 (15)	1980s	0	0	2	0	0	0	
DRC	Mwanbal, 1997 (23)	Feb 1996 - Feb 1997	33	0	20	0	3	0	
RoC	Learned, 2005 (18)I	Apr – Jun 2003	1	1	1	0	0	0	
SS	Formenty, 2010 (14)	2005	1	0	3	0	6	0	
RoC	Reynolds, 2013 (21)	Apr – Nov 2010	3	0	6	1	2	0	
CAR	Berthet, 2011 (9)	Jun 2010	0	0	1	0	1	0	
DRC	McCollum, 2015 (19)	2011-2014	3	3	0	0	25	0	
CAR	Nakouné, 2017;	Dec 2015 - Feb 2016	1	1	2	1	10	1	
DRC	Kalthan 2016 (16,20) Eltvedt, 2020 (12)	Dec 2016	0	0	0	0	3	0	
RoC	Doshi, 2019 (11)	Jan – 5 Apr 2017	5	1	8	1	9	1	
	Total from systematic review studies (1)		212	37	175	13	85	2	
	(1)	CFR:	17.5% (12.6	%, 23.2%)	7.4% (4.	0%, 12.4%)	2.4% (0	.3%, 8.2%)	
	DRC Sitrep 2024 (8)		1832	192	1293	62	1413	42	
	, , ,	CFR:	10.5% (9.19	%, 12.0%)	4.8% (3	.7%, 6.1%)	3.0% (2	.2%, 4.0%)	
	Total		2024	229	1468	75	1498	44	
		CFR:	11.2% (9.9%	, 12.7%)	5.1% (4	.0%, 6.4%)	2.9% (2	.1%, 3.9%)	

* CAR = Central African Republic, RC = Democratic Republic of the Congo, RoC = Republic of the Congo, SS = South Sudan; Based on 472 / 550 cases for which age-band could be definitively determined

There were striking differences in case outcomes by vaccination status (Figure 2A); The crude CFR in the systematic review data was highest among unvaccinated individuals at 13.8% (n=42/263; 95%CI:10.1%-18.2%) (Figure 2B). By comparison, there were no recorded deaths among 51 cases in confirmed vaccinees. Indeed, the only fatal case that could potentially have been vaccinated was documented in a 40-year-old man, who was

born three years before the cessation of smallpox vaccination in 1980 (11). The majority of cases in the systematic review data were recorded during the early 1980s outbreak in DRC (Figure 2C) (22), giving limited power to resolve temporal trends in CFR (Figure 2D).





Figure 2 Case outcomes in studies identified by the Bunge et al. systematic review (1). A) by vaccination status with B) corresponding crude case fatality ratio (CFR); and C) in each five-year period since 1970 with D) corresponding crude CFR. In CFR plots (B,D), points depict the central estimate (deaths / cases) with error bars showing 95% exact binomial confidence intervals. Dashed horizontal lines and shaded bands show overall CFR (all ages, vaccine status and years) with 95% CI.

Modelling the CFR

To formally characterise age variation in CFR while accounting for the potential confounding effects of temporal trends and differences in vaccine coverage by age, we fitted binomial regression models to the data reported in the systematic review (1). Leave-one-out cross validation confirmed that predictive performance was better for models assuming age dependence followed a Hill function (M7-10) than when logistic age dependence was assumed (M1,4-6) or models without age-dependence (M2-3), based on a difference in the expected log posterior density (ELPD) >4 (Table S1). Increasing age was significantly associated with a decline in severity in all models. Modelling CFR as a Hill function of age only (M7), provided the best fit to data based on smallest ELPD, and capture. Comparing the modelled CFR by age-band to observed estimates from the data showed good correspondence (Figure S1). The posterior estimates of a_{50} and b were 2.9 (95% Crl 0.5 - 8.3) and 1.4 (95% Crl: 0.7 - 2.3) suggesting a near-reciprocal relationship between CFR and age. We estimate that CFR declines steeply from 26% (95%Crl 15% - 43%) at age 1 to 5% (95%Crl 3% - 8%) by age 10, falling to 1% (95%Crl 0% 0%) by age 30 (Figure 3).



solid line depicts the median posterior estimate, with shaded bands showing the 50% and 95% credible intervals. Points are coloured according to study and show the outcome of individual cases where reported (0 = recovery, 1 = death). Larger points depict the crude CFRs calculated in studies reporting outcome by age-group (plotted according to the middle age in the group range), with point size reflecting the number in each group.

Models that incorporated vaccination status in addition to age (M8,10) had similar ELPD (albeit with substantial uncertainty) to the simpler model including age only (M7), indicating that the inclusion of vaccine status did not substantially improve model fit. However, there was some suggestion of a protective effect of vaccination. Adding an effect of vaccination to the best fit model (M7) gave an estimated vaccine effectiveness (VE) against death of 44% (94%Crl: -55%, 94%), with 86% of posterior samples giving VE greater than zero (model M8

Figure 3 Estimated CFR by age for mpox clade I under Model 7 (Hill function, age-only). The

in Table S1). The posterior mean estimate was lowered by the deliberately conservative

231

232

233234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

prior on vaccine effect, however the marginal posterior modal estimate was VE = 74% (Figure S 2). Repeating the analysis assuming a more biologically plausible $\phi \sim U[0,1]$ prior gave an estimated vaccine effectiveness (VE) against death of 57% (94%CrI: 6%, 95%). While models incorporating year of onset had similar ELPD values to the best-fitting ageonly model (M7), there were insufficient data in recent years to be informative about changes in the CFR over time, with little evidence to distinguish the estimate of $\theta_{v=2024}$ from its prior (Figure S 2). We assessed the sensitivity of our results to the assumption that individuals born before 1980 whose vaccine status was unknown were 'probable' vaccinees. Refitting the models excluding these 42 cases (including one death) produced similar ELPD estimates for all Hill function models, however the model incorporating vaccination (M8) had the lowest value overall, with similar parameter estimates and quality of fit to the main results (Table S2; Figure S3; Figure S4). While the analysis was underpowered to provide a statistically significant estimate of vaccine protection against death, the posterior was maximized at VE = 88% (Figure S 5). Analysis including data from DRC sitrep We repeated model parameter estimation incorporating the data on mpox cases and deaths by age band (<1y, 1-4y, 5-14y, 15y+) reported in the 2024 DRC sitrep. Inclusion of the sitrep data changed the preferred model; Leave-one-out cross validation selected Model 10, where CFR was modelled as a Hill function of age and depended on both vaccination status and calendar time (Figure 4). The magnitude of the age-effect was diminished compared with the model fit based on historic data alone: the inferred CFR at age 0 was lower at 23% (95% Crl: 13% - 40%) in 1970 falling to 14% (95% Crl: 10% - 22%) in 2024, compared with 42% (95% Crl 15% - 93%) when the sitrep data was not included (Table S 3). Estimated vaccine efficacy against death increased to a mean of 64% (95% CrI: -2% - 96%) with 97% posterior support that vaccine efficacy was >0, with the posterior maximised at VE = 82% (Figure S 6). In addition, the estimate of a_{50} increased to 6.8y (95% CrI: 1.6y – 12.9y) and that of b, the slope of the Hill function, decreased to 0.91 (95% Crl: 0.57–1.28) (Table S 3)




Figure 4 Estimated CFR by age, inferred vaccination status, and year of onset for mpox clade I under Model 10 (Hill, age, vaccination status, year) based on data incorporating the DRC 2024 sitrep. Solid lines depict the median posterior estimate for the posterior mean CFR at each age inferred for 1970 and 2024, with shaded bands showing the 50% and 95% credible intervals. Points are coloured according to year of outbreak and show the outcome of individual cases where reported (0 = recovery, 1 = death). Larger points depict the crude CFRs calculated in studies reporting outcome by age-group (plotted according to the median age in the group, where reported and mid-point of the age range otherwise), with point size reflecting the number in each group.

We assessed the sensitivity of these results to uncertainty around the age of adult cases in the 2024 DRC outbreak. In the analysis presented above, we assumed that the mean age of cases in the 15+ age group was 34y (in line with DRC demography). Reducing the average age of adult cases to 21y and repeating the analysis produced qualitatively unchanged results in terms of model selection and parameter estimates for the better fitting Hill function models (Table S4; Figure S8; Figure S 9; Figure S10).

Table 2 tabulates CFR estimates for two of the best fitting model variants from the main analysis and the best fitting model from the supplementary analysis which also included the 2024 DRC sitrep data.

Table 2 Modelled clade I case fatality ratio (CFR; %) by age, based on posterior mean and 95% credible interval for models M7 (Hill function, age-only) and M8 (Hill function, age and vaccination status) for the main analysis (including data from the Bunge et al. systematic review) and M10 for the analysis additionally incorporating data from the 2024 DRC sitrep, presenting CFR for 2024.

Data	Bunge	e et al. systematic r	Including DRC sitrep			
Model	M7: Hill, age	M8: Hill, age,	vaccination	M10: Hill, age, year=2		
Age		Unvaccinated	Vaccinated	Unvaccinated	Vaccinated/	
5	9.7 (6.9 - 13.0)	10.2 (7.3 - 13.7)	4.8 (0.6 - 14.7)	11.9 (10.2 - 13.7)	4.8 (0.7 - 15.6)	
10	4.7 (2.6 - 7.9)	5.4 (2.8 - 9.8)	2.5 (0.3 - 7.5)	8.2 (7.3 - 9.3)	3.3 (0.5 - 10.5)	
15	2.9 (1.2 - 6.0)	3.5 (1.4 - 8.3)	1.6 (0.2 - 5.2)	6.0 (5.2 - 6.9)	2.4 (0.3 - 7.6)	
20	2.1 (0.7 - 4.8)	2.6 (0.8 - 7.3)	1.2 (0.1 - 4.1)	4.7 (3.9 - 5.5)	1.9 (0.3 - 6.0)	
25	1.6 (0.5 - 4.2)	2.0 (0.5 - 6.6)	0.9 (0.1 - 3.4)	3.9 (3.1 - 4.7)	1.5 (0.2 - 4.9)	
30	1.2 (0.3 - 3.7)	1.6 (0.4 - 6.0)	0.7 (0.1 - 2.9)	3.3 (2.6 - 4.1)	1.3 (0.2 - 4.2)	
35	1.0 (0.2 - 3.3)	1.3 (0.3 - 5.5)	0.6 (0.1 - 2.6)	2.8 (2.1 - 3.7)	1.1 (0.2 - 3.7)	
40	0.9 (0.2 - 3.0)	1.2 (0.2 - 5.2)	0.5 (0.1 - 2.3)	2.5 (1.8 - 3.4)	1.0 (0.1 - 3.3)	

DISCUSSION

276277

278

279

280

281

282

283

284

285

286287

288

289

290

291

292

293

294295

296

297

298

299

300

Our analysis provides strong evidence for variation in the CFR of mpox clade I by age in endemic regions. Modelling based on data included in the Bunge et al. systematic review suggests a near-reciprocal relationship between the CFR and age, with estimates of 9.7% (95% Crl 6.9% - 13.0%) for children aged 5, to 1.2% (95% Crl 0.3% - 3.7%) by age 30. While incorporating probable smallpox vaccination status in addition to age did not improve the model's predictive ability, posterior estimates indicate protection against death for individuals who are vaccinated but nevertheless become symptomatically infected with mpox, although our analysis of the scant historical data was statistically underpowered with broad credible intervals overlapping zero. Cases and deaths from the DRC epidemic reported in the first 12 weeks of 2024 imply a CFR of 10.5% (n=192/1832; 95% CI: 9.1%-12.0%) in <5s, 4.8% (n=62/1293; 95% CI: 3.7%-6.1%) in 5-14 year olds, and 3.0% (n=42/1413; 95% CI: 2.2%- 4.0%) in over 15s (8). Reanalysis of the CFR combining these data with the earlier data collated by Bunge et al. showed age was still the most important determinant of severity. However, the magnitude of age differences was diminished compared with the analysis of data from the systematic review. With the expanded dataset, the model incorporating vaccination status and calendar time in addition to age was preferred over the model of age only. There was strong posterior support for a protective effect against death, with a vaccine efficacy estimate of 64% (95%

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

Crl: -2% - 96%). In addition, there was support for a reduction in CFR between 1970 and 2024, although this was driven entirely by the 2024 outbreak data. The cause for the reduction in severity is unclear with potential contributing factors including differences in case ascertainment, improvements in population health and/or access to care, or changing virulence as the clade evolves, with further work needed to attribute causality and implications. A key strength of our analysis include is its synthesis of evidence from systematically identified outbreaks within a robust Bayesian framework incorporating model selection to provide the first quantitative estimates of the CFR for clade I mpox in endemic settings. However, there are also important limitations. Transmission of mpox clade I is concentrated in central Africa and has not caused major outbreaks outside of this endemic region to date. As such, our analysis is restricted to cases from DRC, Republic of Congo, Central African Republic, and South Sudan. The level of surveillance, case ascertainment, prevalence of comorbidities, and access to healthcare vary substantially between settings worldwide, so estimates of severity presented here are not necessarily transferrable to other contexts. We did not have data on underlying heterogeneities in susceptibility to severe mpox outcomes, which may be associated with age. Qualitatively, case reports of clade I infections reveal comorbidities, such as measles co-infection, and preventable exacerbating conditions, such as dehydration and bacterial superinfection of lesions, suggesting wide scope for improvement of outcomes with appropriate care (16,20,22). In the absence of genomic evidence, we considered cases to part of clade I based on location, in accordance with the systematic review underlying the analysis and geographical spread described by WHO (1). Transmission of clade II in clade I endemic areas could therefore lead to misspecification, although prior to the 2022 clade IIb outbreak this is likely to have been minimal. The interpretation and applicability of our CFR estimates depends upon both case definition and ascertainment, which will vary depending on reporting system, e.g. via surveillance or active epidemiological investigation. Severe cases, especially those with fatal outcomes, are more likely to be identified than mild infections, which may lead to CFR being overestimated. Furthermore, if reporting of severe outcomes is associated with age, for example if deaths in children are more likely to be reported than deaths in adults, the concentration of severity at young ages may be overestimated, however it is equally likely that case ascertainment overall is higher in children. The data underlying our analysis were limited and restricted to the details provided in published case reports, with the quantity and quality of

336

337338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360361

362

363

364

365

366

367

368

data varying between outbreaks and locations. Case ascertainment in the current DRC epidemic is unclear with the majority of cases being suspected but unconfirmed; due to diagnostic capacity constraints, only around 10% of suspected cases are sampled for laboratory analysis. As such, some suspected mpox cases could be misattributed, leading to potential inclusion of other diseases that cause skin lesions, such as chickenpox, in the case count. Furthermore, as the DRC epidemic is ongoing, right-censoring of case-outcomes in the naïve estimator (29) may lead to CFR being underestimated – perhaps explaining the apparent reduction in CFR over time seen in our analysis which included 2024 DRC data in the case count. Smallpox vaccination status was confirmed in only 65% of case reports in the systematic review and none of the 2024 DRC sitrep cases, so we inferred probable vaccination status based on birth dates. The implicit assumption that all birth cohorts before 1980 were vaccinated likely overestimates coverage in older age groups, as it exceeds the 80% target coverage set by WHO during its smallpox vaccination campaign (3), we addressed this limitation by including a sensitivity analysis excluding the 42 individuals born before 1980 whose vaccine status was unconfirmed, which favoured the model including age and vaccination status (M8) over age alone (M7), but otherwise made little qualitative difference to our results. Furthermore, misclassifying fatal case outcomes as being vaccinated lowers estimates of vaccine efficacy, making the assumption conservative in this respect. While data from the ongoing DRC outbreak suggest a reduction in the CFR over time, an increase in sexual transmission of clade I mpox may adversely impact future trends in severity. During the 2022 clade IIb outbreak, people living with HIV were more likely to be infected with mpox, and those with advanced HIV infection were more likely to suffer severe mpox disease and death, indicating increased severity due to immune compromise (30). HIV prevalence is <1% in DRC (among 83% of people who know their status) but this rises to 7% in key populations (7), and we currently lack clade I CFR estimates in immunocompromised patients. In conclusion, age dependent severity, together with the concentration of susceptibility to mpox infection at young ages due to lack of prior infection and the discontinuation of smallpox vaccination, raises important questions for future epidemic response. Despite mounting reports of sexual transmission of clade I infection in the ongoing DRC outbreak, the majority of cases are still reported in young children, suggestive of a generalised epidemic with sustained community transmission. Additional epidemiological studies backed by mathematical modelling are urgently needed to help decision-makers understand the

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

interaction between drivers of transmission and the age-patterns of severity we present here, and their implications for targeting future vaccination campaigns. **Contributors** The study was conceived by LKW. Study data was extracted by LKW. The analysis was designed and implemented by LKW with input from NMF. The report was drafted by LKW and revised by all authors. All authors had access to the data and accept responsibility for submission for publication. **Declaration of interests** LKW reports personal fees from WHO-EURO for consulting on the 2022-23 Mpox clade II outbreak. LKW reports grants from the Wellcome Trust and NIHR, personal fees from Pacific Life Re, honoraria from the Luxembourg National Research Fund and Lancet Infectious Diseases for rapid peer review, and participating on a DSMB for the Wellcome Trust, all outside the submitted work. NMF reports grants from the Wellcome Trust, NIHR, the Bill and Melinda Gates Foundation, Gavi, a philanthropic donation from Community Jameel and fees for journal editing from eLife. Data sharing All data and code to reproduce the analysis are available at https://github.com/mrcide/mpox clade i severity **Funding** LKW acknowledges funding from the Wellcome Trust (grant number 218669/Z/19/Z). LKW and NMF acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. NMF acknowledges funding provided by the NIHR Health Protection Unit in Modelling and Health Economics (reference NIHR200908) and the Jameel Institute (supported by a philanthropic donation from Community Jameel). The views expressed are those of the authors and not necessarily those of the funders. License For the purpose of open access, the author has applied a 'Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.

REFERENCES

- 401 1. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing
- 402 epidemiology of human monkeypox—A potential threat? A systematic review. PLoS
- 403 Negl Trop Dis. 2022;16(2):1–20.
- 404 2. Deputy NP, Deckert J, Chard AN, Sandberg N, Moulia DL, Barkley E, et al. Vaccine
- 405 Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med.
- 406 2023 Jun 29;388(26):2434–43.
- 407 3. Taube JC, Rest EC, Lloyd-Smith JO, Bansal S. The global landscape of smallpox
- 408 vaccination history and implications for current and future orthopoxvirus susceptibility: a
- 409 modelling study. Lancet Infect Dis. 2022 Nov;S1473309922006648.
- 4.1 World Health Organization. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends
- 411 [Internet]. [cited 2023 Sep 14]. Available from:
- 412 https://worldhealthorg.shinyapps.io/mpx_global/#2_Global_situation_update
- 413 5. Ulaeto D, Agafonov A, Burchfield J, Carter L, Happi C, Jakob R, et al. New nomenclature
- for mpox (monkeypox) and monkeypox virus clades. Lancet Infect Dis. 2023
- 415 Mar;23(3):273.
- 416 6. Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, et al. Monkeypox.
- 417 Lancet Lond Engl. 2023 Jan 7;401(10370):60–74.
- 418 7. Mpox (monkeypox)- Democratic Republic of the Congo [Internet]. [cited 2023 Dec 5].
- 419 Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2023-
- 420 DON493
- 421 8. La variole simienne (monkeypox) en République démocratique du Congo: Rapport de la
- Situation Epidemiologique Sitrep N°005 (du 18 24 mars 2024) Democratic Republic of

- 423 the Congo | ReliefWeb [Internet]. 2024 [cited 2024 Apr 10]. Available from: 424 https://reliefweb.int/report/democratic-republic-congo/la-variole-simienne-monkeypox-enrepublique-democratique-du-congo-rapport-de-la-situation-epidemiologique-sitrep-425 426 no005-du-18-24-mars-2024 427 9. Berthet N, Nakouné E, Whist E, Selekon B, Burguière AM, Manuguerra JC, et al. 428 Maculopapular lesions in the Central African Republic. The Lancet. 2011 Oct 429 8;378(9799):1354. 430 10. Breman JG, Kalisa-Ruti, Steniowski MV, Zanotto E, Gromyko Al, Arita I. Human 431 monkeypox, 1970-79. Bull World Health Organ. 1980;58(2):165-82. 432 11. Doshi RH, Guagliardo SAJ, Doty JB, Babeaux AD, Matheny A, Burgado J, et al. 433 Epidemiologic and Ecologic Investigations of Monkeypox, Likouala Department. 434 Republic of the Congo, 2017. Emerg Infect Dis. 2019 Feb;25(2):273–81. 435 12. Eltvedt AK, Christiansen M, Poulsen A. A Case Report of Monkeypox in a 4-Year-Old 436 Boy from the DR Congo: Challenges of Diagnosis and Management. Case Rep Pediatr. 2020 Apr 9;2020:e8572596. 437 438 13. Jezek Z, Arita I, Mutombo M, Dunn C, Nakano JH, Szczeniowski M. Four generations of 439 probable person-to-person transmission of human monkeypox. Am J Epidemiol. 1986 440 Jun;123(6):1004-12. 14. Formenty P, Muntasir MO, Damon I, Chowdhary V, Opoka ML, Monimart C, et al. 441 442 Human Monkeypox Outbreak Caused by Novel Virus Belonging to Congo Basin Clade,
- 15. Herve VMA, Belec L, Yayah G, Georges AJ. Monkeypox in central africa. About two
 strains isolated in Central African Republic. Med Mal Infect. 1989 May;19(5):322–4.

Sudan, 2005. Emerg Infect Dis. 2010 Oct;16(10):1539–45.

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

16. Kalthan E, Dondo-Fongbia JP, Yambele S, Dieu-Creer LR, Zepio R, Pamatika CM. Epidémie de 12 cas de maladie à virus monkeypox dans le district de Bangassou en République Centrafricaine en décembre 2015. Bull Société Pathol Exot. 2016 Dec 1;109(5):358–63. 17. Khodakevich L, Widy-Wirski R, Arita I, Marennikova SS, Nakano J, Meunier D. Monkey pox virus infection in humans in the Central African Republic. Bull Soc Pathol Exot Filiales. 1985 Jan 1;78(3):311–20. 18. Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg. 2005 Aug;73(2):428–34. 19. McCollum AM, Nakazawa Y, Ndongala GM, Pukuta E, Karhemere S, Lushima RS, et al. Human Monkeypox in the Kivus, a Conflict Region of the Democratic Republic of the Congo. Am J Trop Med Hyg. 2015 Oct 7;93(4):718-21. 20. Nakoune E, Lampaert E, Ndiapou SG, Janssens C, Zuniga I, Van Herp M, et al. A Nosocomial Outbreak of Human Monkeypox in the Central African Republic. Open Forum Infect Dis. 2017 Nov 3;4(4):ofx168. 21. Reynolds MG, Emerson GL, Pukuta E, Karhemere S, Muyembe JJ, Bikindou A, et al. Detection of Human Monkeypox in the Republic of the Congo Following Intensive Community Education. Am J Trop Med Hyg. 2013 May 1;88(5):982–5. 22. Jezek Z, Grab B, Szczeniowski M, Paluku KM, Mutombo M. Clinico-epidemiological features of monkeypox patients with an animal or human source of infection. Bull World Health Organ. 1988;66(4):459-64.

468 23. Mwanbal. Human Monkeypox -- Kasai Oriental, Zaire, 1996-1997 [Internet]. [cited 2023 469 Dec 5]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00048673.htm 470 24. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features 471 of 282 patients. J Infect Dis. 1987 Aug;156(2):293-8. 472 25. Bürkner PC. Bayesian Item Response Modeling in R with brms and Stan. J Stat Softw. 473 2021 Nov 30;100:1-54. 474 26. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A 475 Probabilistic Programming Language. J Stat Softw. 2017 Jan 11;76:1–32. 476 27. Vehtari A, Gelman A, Gabry J. Practical Bayesian model evaluation using leave-one-out 477 cross-validation and WAIC. Stat Comput. 2017;27(5):1413–32. 478 28. Paananen T, Piironen J, Bürkner PC, Vehtari A. Implicitly adaptive importance sampling. 479 Stat Comput. 2021 Feb 9;31(2):16. 480 29. Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, et al. Methods for 481 estimating the case fatality ratio for a novel, emerging infectious disease. Am J

482

483

484

485

486

Epidemiol. 2005;162(5):479-86.

30. Yinka-Ogunleye A, Dalhat M, Akinpelu A, Aruna O, Garba F, Ahmad A, et al. Mpox

study in Nigeria. BMJ Glob Health. 2023 Nov 30;8(11):e013126.

(monkeypox) risk and mortality associated with HIV infection: a national case-control

Supplementary Appendix

Main analysis: systematic review data




Figure S1 Observed vs expected case fatality ratio by age-group under best-fitting model to data extracted from the Bunge et al. systematic review, M7 (Hill function, age-only). Bars show mean and 95% credible intervals predicted by the model. Points and bars show the crude CFR calculated from the data and 95% binomial confidence intervals.




Figure S 2 Posterior parameter densities for Hill function models of clade I CFR (M6-10) fitted to data extracted from the Bunge et al. systematic review.

Table S1 Description of fitted binomial regression models and posterior parameter estimates fitted to data reported in the Bunge et al systematic review (1), with difference in the expected log posterior density (ELPD) for each model compared to the best-fitting model (M7).

		$ heta_{1970}$	$ heta_{2024}$	φ	a_{50}	b	Difference in ELPD
		CFR at	age zero	Vaccine effectiveness against death	Age of 50% maximum CFR	Slope of Hill function	Mean (s.e.)
M	Description \ Prior	~ U	(0,1)	$\sim U(-1,1)$	$\sim U[0,70]$	$\sim U[0,3]$	
1	Logistic, age only	0.248 (0.098,0.414)			7.133 (0.137,49.591)	0.176 (0.053,0.746)	-8.9 (4.7)
2	No age, vaccination status only	0.111 (0.085,0.142)		0.808 (0.474,0.977)	,	,	-6.0 (6.5)
3	No age, year of onset only	0.106 (0.066,0.151)	0.081 (0.024,0.152)	,			-13.1 (7.8)
4	Logistic, age and vaccination status	0.173 (0.089,0.360)	, ,	0.703 (0.027,0.968)	31.844 (0.431,68.388)	0.777 (0.023,2.838)	-8.5 (5.7)
5	Logistic, age and year of onset	0.247 (0.104,0.433)	0.382 (0.103,0.819)	,	3.696 (0.073,16.541)	0.149 (0.059,0.252)	-8.9 (4.9)
6	Logistic, age, vaccination status, year of onset	0.207 (0.086,0.394)	0.258 (0.042,0.714)	0.633 (-0.230,0.963)	20.846 (0.127,67.362)	0.526 (0.020,2.783)	-9.7 (5.7)
7	Hill, age only	0.424 (0.154,0.928)			2.860 (0.464,8.310)	1.358 (0.721,2.275)	Ref
8	Hill, age and vaccination status	0.400 (0.144,0.917)		0.441 (-0.548,0.942)	3.773 (0.424,14.037)	1.261 (0.607,2.198)	-0.5 (1.4)
9	Hill, age and year of onset	0.372 (0.107,0.892)	0.570 (0.178,0.972)	, ,	2.469 (0.519,6.326)	1.390 (0.764,2.320)	-0.3 (0.9)
10	Hill, age, vaccination status, year of onset	0.374 (0.112,0.881)	0.548 (0.155,0.966)	0.412 (-0.649,0.929)	2.961 (0.459,8.334)	1.290 (0.633,2.250)	-0.5 (1.6)

Sensitivity analysis: excluding 'probable' vaccinees




Figure S3 Estimated CFR by age and inferred vaccination status for mpox clade I under Model 8 (Hill, age and vaccination status) in the sensitivity analysis using data extracted from the Bunge et al. systematic review but excluding all cases born before 1980 whose vaccination status was unconfirmed (previously classified as 'probable' vaccinees). Solid lines depict the median posterior estimate for probable/vaccinated and doubtful/unvaccinated individuals, with shaded bands showing the 50% and 95% posterior predictive intervals. Points are coloured according to inferred vaccination status and show the outcome of individual cases where reported (0 = recovery, 1 = death). Larger points depict the crude CFRs calculated in studies reporting outcome by age-group (plotted according to the median age in the group, where reported and mid-point of the age range otherwise), with point size reflecting the number in each group.




Figure S4 Observed vs expected case fatality ratio by age-group and vaccination status under best-fitting model (M8: Hill function, age and vaccination) in the sensitivity analysis using data extracted from the Bunge et al. systematic review but excluding all cases born before 1980 whose vaccination status was unconfirmed (previously classified as 'probable' vaccinees). Bars show mean and 95% credible intervals predicted by the model. Points and bars show the crude CFR calculated from the data and 95% binomial confidence intervals.




Figure S 5 Posterior parameter densities for Hill function models of clade I CFR (M6-10) fitted to data extracted from the Bunge et al. systematic review but excluding all cases born before 1980 whose vaccination status was unconfirmed (previously classified as 'probable' vaccinees)

		θ_{1970}	θ_{2024}	ф	a ₅₀	b	Difference in ELPD
		CFR at	age zero	Vaccine efficacy against death	Age of 50% maximum CFR	Slope of Hill function	Mean (s.e.)
M	Description \ Prior	~ U	(0, 1)	$\sim U(-1,1)$	$\sim U[0,70]$	$\sim U[0,3]$	
1	Logistic, age only	0.326 (0.148,0.554)			3.249 (0.102,12.104)	0.225 (0.104,0.362)	-4.4 (3.2)
2	No age, vaccination status only	0.111 (0.084,0.142)		0.823 (0.335,0.995)	,	,	-7.4 (6.4)
3	No age, year of onset only	0.117 (0.071,0.164)	0.080 (0.020,0.161)	, ,			-12.9 (6.6)
4	Logistic, age and vaccination status	0.301 (0.105,0.524)	,	0.468 (-0.701,0.985)	6.487 (0.091,48.082)	0.307 (0.085,2.079)	-5.3 (3.3)
5	Logistic, age and year of onset	0.304 (0.130,0.542)	0.491 (0.139,0.938)	, ,	2.316 (0.077,7.766)	0.230 (0.114,0.353)	-4.4 (3.3)
6	Logistic, age, vaccination status, year of onset	0.302 (0.123,0.538)	0.464 (0.103,0.925)	0.415 (-0.782,0.984)	3.126 (0.066,13.365)	0.235 (0.098,0.370)	-4.6 (3.3)
7	Hill, age only	0.379 (0.150,0.890)	,	,	3.400 (0.599,8.660)	1.568 (0.808,2.660)	-0.4 (0.5)
8	Hill, age and vaccination status	0.369 (0.147,0.879)		0.454 (-0.747,0.984)	3.715 (0.556,9.976)	1.517 (0.741,2.714)	Ref
9	Hill, age and year of onset	0.355 (0.106,0.869)	0.508 (0.145,0.946)	, , ,	2.893 (0.629,6.999)	1.574 (0.832,2.644)	-0.9 (0.8)
10	Hill, age, vaccination status, year of onset	0.362 (0.110,0.859)	0.505 (0.134,0.952)	0.440 (-0.736,0.983)	2.982 (0.600,7.612)	1.493 (0.765,2.578)	-0.5 (0.7)

525

Analysis incorporating DRC sitrep data




Figure S 6 Posterior parameter densities for Hill function models of clade I CFR (M6-10) fitted to data data extracted from the Bunge et al. systematic review and additionally incorporating the DRC 2024 sitrep data.




Figure S7 Observed vs expected case fatality ratio by age-group and vaccination status under best-fitting model (M10: Hill function, age, vaccination status, year of onset) based on data incorporating the DRC 2024 sitrep. Bars show mean and 95% credible intervals predicted by the model. Points and bars show the crude CFR calculated from the data and 95% binomial confidence intervals.

Table S 3 Description of fitted binomial regression models and posterior parameter estimates including DRC data, with difference in the expected log posterior density (ELPD) for each model compared to the best-fitting model (M10).

		$ heta_{1970}$	$ heta_{2024}$	φ	a_{50}	b	Difference in ELPD
		CFR at	age zero	Vaccine efficacy against death	Age of 50% maximum CFR	Slope of Hill function	Mean (s.e.)
M	Description \ Prior	~ U	(0,1)	$\sim U(-1,1)$	$\sim U[0,70]$	$\sim U[0,3]$	
1	Logistic, age only	0.180 (0.128,0.221)			4.602 (0.134,14.609)	0.066 (0.051,0.083)	-14.0 (11.3)
2	No age, vaccination status only	0.069 (0.063,0.077)		0.691 (0.124,0.963)	,	,	-54.0 (29.7)
3	No age, year of onset only	0.111 (0.078,0.150)	0.066 (0.059,0.073)	, ,			-57.7 (28.4)
4	Logistic, age and vaccination status	0.181 (0.128,0.221)	, ,	0.548 (-0.240,0.945)	4.718 (0.128,15.009)	0.065 (0.051,0.082)	-12.5 (10.9)
5	Logistic, age and year of onset	0.245 (0.153,0.348)	0.177 (0.128,0.215)	,	4.173 (0.112,13.668)	0.064 (0.050,0.081)	-16.0 (10.4)
6	Logistic, age, vaccination status, year of onset	0.265 (0.166,0.376)	0.175 (0.124,0.214)	0.661 (0.049,0.959)	4.424 (0.126,14.897)	0.063 (0.048,0.080)	-13.2 (9.4)
7	Hill, age only	0.138 (0.108,0.182)	,	,	7.928 (3.361,13.323)	1.015 (0.687,1.387)	-2.6 (4.4)
8	Hill, age and vaccination status	0.138 (0.108,0.184)		0.526 (-0.280,0.944)	8.030 (3.226,13.875)	1.006 (0.681,1.396)	-1.5 (4.0)
9	Hill, age and year of onset	0.215 (0.129,0.360)	0.144 (0.108,0.208)	,	6.708 (1.798,12.283)	0.930 (0.595,1.302)	-2.4 (2.4)
10	Hill, age, vaccination status, year of onset	0.232 (0.138,0.392)	0.143 (0.107,0.211)	0.643 (-0.015,0.958)	6.800 (1.604,12.862)	0.905 (0.570,1.279)	Ref

Sensitivity analysis: average age of cases in DRC sitrep data




Figure S8 Estimated CFR by age, inferred vaccination status, and year of onset for mpox clade I under Model 10 (Hill, age, vaccination status, year) in the sensitivity analysis using data incorporating the 2024 DRC sitrep but assuming an average age of 21y among cases >15y. Solid lines depict the median posterior estimate for the posterior mean CFR at each age inferred for 1970 and 2024, with shaded bands showing the 50% and 95% credible intervals. Points are coloured according to year of outbreak and show the outcome of individual cases where reported (0 = recovery, 1 = death). Larger points depict the crude CFRs calculated in studies reporting outcome by age-group (plotted according to the median age in the group, where reported and mid-point of the age range otherwise), with point size reflecting the number in each group.




Figure S 9 Posterior parameter densities for Hill function models of clade I CFR (M6-10) fitted to data data extracted from the Bunge et al. systematic review and additionally incorporating the DRC 2024 sitrep data, assuming an average age of 21y among cases >15y




Figure S10 Observed vs expected case fatality ratio by age-group and vaccination status under best-fitting model (M10: Hill function, age, vaccination status and year) based on data incorporating the DRC 2024 sitrep, assuming an average age of 21y among cases >15y. Bars show mean and 95% credible intervals predicted by the model. Points and bars show the crude CFR calculated from the data and 95% binomial confidence intervals.

Table S4 Posterior parameter estimates including DRC sitrep data assuming an average age of 21y among cases >15y, with difference in the expected log posterior density (ELPD) for each model compared to the best-fitting model (M10).

		θ ₁₉₇₀	θ_{2024}	ф	a ₅₀	b	Difference in ELPD
		CFR at	age zero	Vaccine efficacy against death	Age of 50% maximum CFR	Slope of Hill function	Mean (s.e.)
M	Description \ Prior	~ U	(0, 1)	$\sim U(-1,1)$	$\sim U[0,70]$	$\sim U[0,3]$	
1	Logistic, age only	0.202 (0.144,0.251)			2.838 (0.086,8.626)	0.106 (0.084,0.132)	-4.7 (6.4)
2	No age, vaccination status only	0.069 (0.063,0.077)		0.691 (0.124,0.963)	,	, , ,	-57.7 (31.5)
3	No age, year of onset only	0.111 (0.078,0.150)	0.066 (0.059,0.073)				-61.4 (30.1)
4	Logistic, age and vaccination status	0.202 (0.142,0.250)	,	0.426 (-0.507,0.922)	2.945 (0.089,9.112)	0.106 (0.084,0.132)	-4.1 (6.3)
5	Logistic, age and year of onset	0.281 (0.177,0.400)	0.198 (0.143,0.243)		2.588 (0.083,8.162)	0.104 (0.083,0.128)	-5.3 (5.1)
6	Logistic, age, vaccination status, year of onset	0.295 (0.183,0.421)	0.196 (0.139,0.241)	0.552 (-0.272,0.946)	2.714 (0.089,8.553)	0.103 (0.082,0.128)	-4.3 (5.0)
7	Hill, age only	0.131 (0.106,0.163)			7.970 (4.607,11.501)	1.364 (0.928,1.881)	-0.9 (3.7)
8	Hill, age and vaccination status	0.131 (0.107,0.165)		0.428 (-0.516,0.931)	8.012 (4.484,11.535)	1.357 (0.911,1.893)	-0.2 (3.4)
9	Hill, age and year of onset	0.195 (0.122,0.292)	0.131 (0.104,0.169)	,	7.348 (3.749,11.201)	1.269 (0.853,1.800)	-0.4 (2.0)
10	Hill, age, vaccination status, year of onset	0.210 (0.132,0.322)	0.132 (0.105,0.172)	0.579 (-0.186,0.947)	7.274 (3.486,11.241)	1.232 (0.800,1.766)	Ref